We provide you with 20 years of free, institutional-grade data for TCRR stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of TCRR. Explore the full financial landscape of TCRR stock.
| Reported Date | CIK | Ticker | Type |
|---|
TCR2 Therapeutics Inc(NASDAQ:TCRR) 
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is...
Website: http://www.tcr2.com
Founded: 2015
Full Time Employees: 109
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about TCRR stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.